TW200409635A - A pharmaceutical composition containing a HMG-CoA reductase - Google Patents
A pharmaceutical composition containing a HMG-CoA reductase Download PDFInfo
- Publication number
- TW200409635A TW200409635A TW092121123A TW92121123A TW200409635A TW 200409635 A TW200409635 A TW 200409635A TW 092121123 A TW092121123 A TW 092121123A TW 92121123 A TW92121123 A TW 92121123A TW 200409635 A TW200409635 A TW 200409635A
- Authority
- TW
- Taiwan
- Prior art keywords
- thiamine
- blood
- furfuryl alcohol
- pharmaceutical composition
- reductase inhibitor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A61K31/51—Thiamines, e.g. vitamin B1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002225979 | 2002-08-02 | ||
JP2002260719 | 2002-09-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
TW200409635A true TW200409635A (en) | 2004-06-16 |
Family
ID=31497621
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW092121123A TW200409635A (en) | 2002-08-02 | 2003-08-01 | A pharmaceutical composition containing a HMG-CoA reductase |
Country Status (6)
Country | Link |
---|---|
JP (1) | JP2010150288A (fr) |
AU (1) | AU2003252358A1 (fr) |
CA (1) | CA2494801A1 (fr) |
HK (1) | HK1077230A1 (fr) |
TW (1) | TW200409635A (fr) |
WO (1) | WO2004012740A1 (fr) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3875092A4 (fr) * | 2018-11-02 | 2021-12-22 | Kyungpook National University Industry-Academic Cooperation Foundation | Composition de prévention ou de traitement de la dégénérescence maculaire |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS54135740A (en) * | 1978-04-13 | 1979-10-22 | Otsuka Nobuhiro | Method of dissolving oryznol to greases or their products |
EP0904082A4 (fr) * | 1996-04-17 | 2001-09-26 | Merck & Co Inc | Therapie d'association destinee a reduire les risques lies a une maladie cardio-vasculaire |
EP1792616B1 (fr) * | 1997-07-31 | 2009-12-16 | Abbott Respiratory LLC | Composition contenant un inhibiteur de réductase HMG-CoA et un composé d'acide nicotinique destiné au traitement d'hyperlipidémie |
JP3597437B2 (ja) * | 2000-02-10 | 2004-12-08 | 日清オイリオグループ株式会社 | 血中脂質改善機能を有する食用油脂 |
AU2001295991A1 (en) * | 2000-10-23 | 2002-05-06 | Sankyo Company Limited | Compositions for improving lipids in blood |
-
2003
- 2003-08-01 AU AU2003252358A patent/AU2003252358A1/en not_active Abandoned
- 2003-08-01 TW TW092121123A patent/TW200409635A/zh unknown
- 2003-08-01 CA CA002494801A patent/CA2494801A1/fr not_active Abandoned
- 2003-08-01 WO PCT/JP2003/009835 patent/WO2004012740A1/fr not_active Application Discontinuation
-
2005
- 2005-12-23 HK HK05111984A patent/HK1077230A1/xx not_active IP Right Cessation
-
2010
- 2010-03-24 JP JP2010067405A patent/JP2010150288A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2003252358A1 (en) | 2004-02-23 |
JP2010150288A (ja) | 2010-07-08 |
WO2004012740A1 (fr) | 2004-02-12 |
CA2494801A1 (fr) | 2004-02-12 |
HK1077230A1 (en) | 2006-02-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6621534B2 (ja) | 慢性咳の処置のためのオルブピタント | |
ES2232418T3 (es) | Combinaciones de farmacos, que comprenden (e)-acido 7-(4-(4-fluorofenil)-6-isopropil-2-(metil(metil-sulfonil)-amino)-pirimidin-5-il)(3r,5s)-3,5-dihidroxihept-6-enoico y un inhibidor, inductor o substrato para la isoenzima 3a4 de p450. | |
US20150272944A1 (en) | Novel triglyceride reducing agent | |
JP2010077162A (ja) | 血中ホモシステイン低下のための医薬組成物 | |
JP2013237709A (ja) | Pgd2拮抗剤及びヒスタミン拮抗剤からなるアレルギー性鼻炎治療用医薬 | |
JP2003528928A (ja) | β遮断薬およびコレステロール低下薬の新組合せ | |
US20050182036A1 (en) | Medicinal composition containing an HMG-CoA reductase inhibitor | |
CN103874490A (zh) | 咔咯和他汀类药物的组合 | |
AU2001294221B2 (en) | Preventives and remedies for complications of diabetes | |
JP4949661B2 (ja) | HMG−CoAリダクターゼ阻害剤とグルタチオンを含有する医薬組成物 | |
EP2686429A1 (fr) | Compositions, procédé de préparation de ces compositions et méthode de traitement de maladies inflammatoires | |
WO2006102788A1 (fr) | Les hypolipemiants complexes | |
TW200409635A (en) | A pharmaceutical composition containing a HMG-CoA reductase | |
JP4607436B2 (ja) | HMG−CoAリダクターゼ阻害剤を含有する医薬組成物 | |
US20080070938A1 (en) | Medicinal composition for mitigating blood lipid or lowering blood homocysteine | |
JP4896501B2 (ja) | 血中遊離脂肪酸低下作用を有する医薬組成物 | |
JP4611622B2 (ja) | 血中脂質改善又は血中ホモシステイン低下のための医薬組成物 | |
JP4454985B2 (ja) | 血液脂質を低下させるための医薬組成物 | |
CN100415235C (zh) | 含有HMG-CoA还原酶抑制剂的药物组合物 | |
TW200404533A (en) | Blood lipid ameliorant compositions | |
WO2018049989A1 (fr) | Composition pharmaceutique de rosuvastatine calcique et procédé de préparation s'y rapportant | |
US20040186163A1 (en) | Novel combination | |
WO2006057209A1 (fr) | Preparation pharmaceutique pour la diminution du taux sanguin en acides gras libres |